Diabetes/Metabolism Research and Reviews · 2006 · 111 citations · 20 references
MedicineEndocrinologyImmunologyAutoimmunityImmunopathologyPediatric TherapeuticsAutoimmune DiseasesDiabetes ControlDiabetes ManagementDiabetes MellitusDiabetes PharmacotherapyIslet AutoimmunityMannitol UsePeptide-based ImmunotherapyT-cell Mediated Endocrine AutoimmunityType 1 Diabetes PathophysiologyType 1 Diabetes Pharmacotherapy
BACKGROUND: Type 1 diabetes mellitus (T1DM) is a T-cell-mediated autoimmune disease that leads to the destruction of insulin-producing beta cells. Treatment with DiaPep277, a peptide derived from heat-shock protein 60 (hsp60), has been found to slow the deterioration of beta-cell function after clinical onset of diabetes in NOD mice and human adults. Our aim was to evaluate the efficacy and safety of DiaPep277 treatment in attenuating beta-cell destruction in children with recent-onset T1DM. METHODS: A prospective, randomized, double-blind, phase II design was used. The sample included 30 children (19 males) aged 7-14 years who had been diagnosed with T1DM from 53 to 116 days previously, and had basal C-peptide concentrations above 0.1 nmol/L. The children were randomized to receive subcutaneous injections of 1 mg DiaPep277 (15 patients) or 40 mg mannitol (placebo) at entry and at 1, 6, and 12 months. The duration of follow-up was 18 months. The groups were compared for stimulated C-peptide level, exogenous insulin dose, and HbA1c concentration. RESULTS: C-peptide levels similarly decreased over time in the DiaPep277- and placebo-treated patients. There was no significant difference in insulin dose or HbA1c concentration between the groups at any time point. No serious drug-related adverse effects were recorded throughout the study period. CONCLUSIONS: One-year treatment with DiaPep277 at a dosage of 1 mg is safe for use and well tolerated in children with recent-onset T1DM. However, it appears to have no beneficial effect in preserving beta-cell function or improving metabolic control.
20
Breeding of a Non-Obese, Diabetic Strain of Mice
Susumu Makino, Kikuko Kunimoto, Yoshihiro Muraoka et al. · EXPERIMENTAL ANIMALS · 1980 · 1.3K citations · Full text
Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus
Kevan C. Herold, William Hagopian, Julie Auger et al. · New England Journal of Medicine · 2002 · 1.2K citations · Full text
Insulin Needs after CD3-Antibody Therapy in New-Onset Type 1 Diabetes
Bart Keymeulen, Evy Vandemeulebroucke, Anette G. Ziegler et al. · New England Journal of Medicine · 2005 · 1.1K citations · Full text
Medicine, Endocrinology, Immunology +17